Fig. 4: Knockdown of the proteasome components, PSMD1 or PSMD3, resulted in a greater reduction of growth in TKI-resistant compared with TKI-sensitive K562 cells. | Oncogene

Fig. 4: Knockdown of the proteasome components, PSMD1 or PSMD3, resulted in a greater reduction of growth in TKI-resistant compared with TKI-sensitive K562 cells.

From: Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B

Fig. 4

Line graphs show cell growth in K562S (n = 3) and K562R cells (n = 4) expressing shRNA targeting PSMD1 (shPSMD1, (A)) or PSMD3 (shPSMD3, (B)) in the presence and absence of doxycycline (100 ng/ml) to induce the knockdown. Counts were recorded and graphed on a log scale. Error bars represent SEM. *p < 0.05; #p < 0.01.

Back to article page